CN113329760A - 归巢核酸内切酶变体 - Google Patents

归巢核酸内切酶变体 Download PDF

Info

Publication number
CN113329760A
CN113329760A CN201980090016.7A CN201980090016A CN113329760A CN 113329760 A CN113329760 A CN 113329760A CN 201980090016 A CN201980090016 A CN 201980090016A CN 113329760 A CN113329760 A CN 113329760A
Authority
CN
China
Prior art keywords
variant
amino acid
onul
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980090016.7A
Other languages
English (en)
Chinese (zh)
Inventor
乔丹·贾儒尔
凯尔·哈文斯
康斯坦丁·克里斯托莫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of CN113329760A publication Critical patent/CN113329760A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980090016.7A 2018-12-10 2019-12-09 归巢核酸内切酶变体 Pending CN113329760A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862777476P 2018-12-10 2018-12-10
US62/777,476 2018-12-10
PCT/US2019/065211 WO2020123371A2 (en) 2018-12-10 2019-12-09 Homing endonuclease variants

Publications (1)

Publication Number Publication Date
CN113329760A true CN113329760A (zh) 2021-08-31

Family

ID=71076132

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980090016.7A Pending CN113329760A (zh) 2018-12-10 2019-12-09 归巢核酸内切酶变体

Country Status (9)

Country Link
US (2) US12404500B2 (https=)
EP (1) EP3893922A4 (https=)
JP (2) JP2022513750A (https=)
KR (1) KR20210102925A (https=)
CN (1) CN113329760A (https=)
AU (1) AU2019397364B8 (https=)
CA (1) CA3122278A1 (https=)
IL (1) IL283720B2 (https=)
WO (1) WO2020123371A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024503249A (ja) * 2020-12-21 2024-01-25 ２セブンティ バイオ インコーポレイテッド 部位特異的変異導入のための組成物及び方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679959A (zh) * 2007-02-19 2010-03-24 赛莱克蒂斯公司 具有新的底物特异性的laglidadg归巢核酸内切酶变体及其用途
US20140148361A1 (en) * 2010-06-07 2014-05-29 Barry L. Stoddard Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
JP5136766B2 (ja) 2004-12-15 2013-02-06 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル キメラベクター
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
EP2188384B1 (en) 2007-09-27 2015-07-15 Sangamo BioSciences, Inc. Rapid in vivo identification of biologically active nucleases
EP2215223B1 (en) 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
EP2524037B1 (en) 2010-01-12 2018-05-16 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
US9169492B2 (en) 2010-02-05 2015-10-27 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
US20110256607A1 (en) * 2010-04-16 2011-10-20 Georg Hausner Homing endonucleases
US20130337454A1 (en) 2010-10-27 2013-12-19 Philippe Duchateau Method for increasing the efficiency of double-strand break-induced mutagenesis
US8673557B2 (en) 2011-02-28 2014-03-18 Seattle Children's Research Institute Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
US20150166969A1 (en) * 2012-02-24 2015-06-18 Fred Hutchinson Cancer Research Center Compositions and methods for the treatment of hemoglobinopathies
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
US20140015679A1 (en) 2012-07-15 2014-01-16 Green Badge LLC Specialty Plant Moisture Sensing
AU2014266833B2 (en) 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
ES2716867T3 (es) 2013-05-31 2019-06-17 Cellectis Sa Endonucleasa de asentamiento LAGLIDADG que escinde el gen de receptor de células T alfa y usos de la misma
CA2913871C (en) 2013-05-31 2021-07-13 Cellectis A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof
EP3925618A1 (en) 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
JP2019509738A (ja) 2016-03-11 2019-04-11 ブルーバード バイオ， インコーポレイテッド ゲノム編集された免疫エフェクター細胞
US20190161530A1 (en) 2016-04-07 2019-05-30 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions
WO2018022619A1 (en) 2016-07-25 2018-02-01 Bluebird Bio, Inc. Bcl11a homing endonuclease variants, compositions, and methods of use
MA45996A (fr) 2016-08-16 2021-06-02 Bluebird Bio Inc Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
AU2017312132A1 (en) 2016-08-19 2019-03-21 Bluebird Bio, Inc. Genome editing enhancers
WO2018039333A1 (en) * 2016-08-23 2018-03-01 Bluebird Bio, Inc. Tim3 homing endonuclease variants, compositions, and methods of use
KR102451510B1 (ko) * 2016-09-08 2022-10-07 2세븐티 바이오, 인코포레이티드 Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
US11591582B2 (en) * 2016-10-11 2023-02-28 2Seventy Bio, Inc. TCRα homing endonuclease variants
MA46543A (fr) 2016-10-17 2019-08-21 Bluebird Bio Inc Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
CN106749666B (zh) 2016-12-22 2018-12-25 福州大学 一种人源程序性死亡受体hPD-1单克隆抗体
CN106939049B (zh) 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
MA48797A (fr) 2017-05-25 2020-04-08 Bluebird Bio Inc Variants de l'endonucléase cblb , compositions et procédés d'utilisation
US11779654B2 (en) * 2017-10-04 2023-10-10 2Seventy Bio, Inc. PCSK9 endonuclease variants, compositions, and methods of use
WO2020072059A1 (en) * 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
IL283724B1 (en) 2018-12-10 2026-02-01 Genetix Biotherapeutics Inc pdcd-1 homing endonuclease variants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679959A (zh) * 2007-02-19 2010-03-24 赛莱克蒂斯公司 具有新的底物特异性的laglidadg归巢核酸内切酶变体及其用途
US20140148361A1 (en) * 2010-06-07 2014-05-29 Barry L. Stoddard Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YUK-SANG CHAN等: "The Design and In Vivo Evaluation of Engineered I-OnuIBased Enzymes for HEG Gene Drive", PLOS ONE, vol. 8, no. 9, 30 September 2013 (2013-09-30), pages 74254, XP055667345, DOI: 10.1371/journal.pone.0074254 *
张殿宝;施萍;庞希宁;: "人工核酸酶用于基因组定点编辑的研究进展", 基础医学与临床, vol. 33, no. 12, 31 December 2013 (2013-12-31), pages 1634 - 1637 *

Also Published As

Publication number Publication date
IL283720B1 (en) 2025-01-01
US20250368973A1 (en) 2025-12-04
JP2025072470A (ja) 2025-05-09
JP2022513750A (ja) 2022-02-09
AU2019397364B1 (en) 2025-07-17
WO2020123371A2 (en) 2020-06-18
IL283720B2 (en) 2025-05-01
EP3893922A2 (en) 2021-10-20
US12404500B2 (en) 2025-09-02
KR20210102925A (ko) 2021-08-20
US20220119784A1 (en) 2022-04-21
EP3893922A4 (en) 2022-09-14
WO2020123371A3 (en) 2020-08-20
AU2019397364A1 (en) 2021-06-24
CA3122278A1 (en) 2020-06-18
AU2019397364B8 (en) 2025-08-07
IL283720A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
US12264343B2 (en) TCRa homing endonuclease variants
US20250262323A1 (en) Pcsk9 endonuclease variants, compositions, and methods of use
JP2019525759A (ja) Ｂｃｌ１１ａホーミングエンドヌクレアーゼバリアント、組成物、および使用方法
US20220064651A1 (en) Talen-based and crispr/cas-based gene editing for bruton's tyrosine kinase
US20250368973A1 (en) Homing endonuclease variants
JP2024501892A (ja) 新規の核酸誘導型ヌクレアーゼ
TW202246497A (zh) Ｃａｓ１２ｉ２融合分子及其用途
US20220364123A1 (en) Wiskott-aldrich syndrome gene homing endonuclease variants, compositions, and methods of use
US20210230565A1 (en) Bruton's tyrosine kinase homing endonuclease variants, compositions, and methods of use
WO2025153530A1 (en) Albumin-targeted endonucleases, compositions, and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20211028

Address after: 60 Benny street, Cambridge, Massachusetts, USA

Applicant after: 2 savinti biology

Address before: 60 Benny street, Cambridge, Massachusetts, USA

Applicant before: BLUEBIRD BIO, Inc.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20241021

Address after: Denmark bagsvaerd

Applicant after: NOVO NORDISK A/S

Country or region after: Denmark

Address before: 60 Benny street, Cambridge, Massachusetts, USA

Applicant before: 2 savinti biology

Country or region before: U.S.A.